Pharmaceutical

Request for TOC Request for Sample
BUY NOW

North America Lymphedema Treatment Market – Industry Trends and Forecast to 2029

Pharmaceutical | Published Report | Apr 2022 | North America | 350 Pages | No of Tables: 54 | No of Figures: 47

Report Description

North America Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Type (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genitalia, Lower Extremity, Upper Extremity), Age Group (Adult, Pediatric, and Geriatric), Route of Administration (Oral, Injectable, and Topical), End User (Hospital, Ambulatory Surgical Centres, Speciality Clinics, and Others), Distribution Channel (Direct Tender, Pharmacy Stores, and Others) Industry Trends and Forecast to 2029

Get Exclusive Sample Copy of this Report Here

North America Lymphedema Treatment Market Analysis and Insights

Lymphedema commonly affects one of the arms or legs. In some cases, both arms and legs may be affected. Some patients might experience swelling in the head, genitals, or chest.

Lymphedema is incurable, but it can be controlled through right treatment, which can help reduce the swelling and pain.

Complex decongestive therapy (CDT): This starts with an intensive therapy phase, during which the patient receives daily treatment and training. This is followed by the maintenance phase when the patient is encouraged to take over their care using techniques they have been taught.

Get Exclusive Sample Copy of this Report Here

Mutations may cause primary lymphedema in some of the genes involved in developing the lymphatic system. These faulty genes interfere with the lymphatic system's development, undermining its ability to drain fluid properly.

Secondary lymphedema has a number of possible causes, including cancer surgery, radiation therapy, infections, inflammatory conditions, cardiovascular diseases, injury, and trauma

The rising prevalence of cancers and increasing health expenditure have accelerated the need to treat lymphedema in healthcare facilities. The surge in innovations and technologies is also propelling the market's growth.

North America lymphedema treatment market is growing in the forecast year due to the rising players in the market and the availability of advanced imaging products. Along with this, manufacturers are engaged in R&D activity for launching novel products in the market.

The rising number of cancer-related lymphedema patients worldwide and the increased R & D activities are propelling the demand for the North America lymphedema treatment market in the forecast period. However, no cure and the high cost of treatment may hamper the growth of the North America lymphedema treatment market in the forecast period.

Data Bridge Market Research analyses that the North America lymphedema treatment market will grow at a CAGR of 9.7% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Type (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genitalia, Lower Extremity, Upper Extremity), Age Group (Adult, Pediatric, and Geriatric), Route of Administration (Oral, Injectable, and Topical), End User (Hospital, Ambulatory Surgical Centres, Speciality Clinics, and Others), Distribution Channel (Direct Tender, Pharmacy Stores, and Others)

Countries Covered

U.S., Canada, and Mexico

Market Players Covered

Tactile Medical, BIOCOMPRESSION SYSTEMS, Lohmann & Rauscher GmbH & Co. KG, ThermoTek, Essity (BSN medical GmbH), Cardinal Health, Smith+Nephew, Avet Pharmaceuticals Inc., KOYA MEDICAL, SIGVARIS GROUP, AIROS Medical, Inc., Tactile Medical, medi GmbH & Co. KG, PAUL HARTMANN AG, Convatec Inc., 3M, JUZO, Mego Afek ltd, Huntleigh Healthcare Limited, HERANTIS PHARMA Plc, among others

Market Definition

Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid usually drained through the body's lymphatic system. It most commonly affects the arms or legs but can also occur in the chest wall, abdomen, neck, and genitals.

Lymph nodes are an important part of your lymphatic system. Lymphedema can be caused by cancer treatments that remove or damage your lymph nodes. Any problem that blocks the drainage of lymph fluid can cause lymphedema.

Treatment may include compression bandages, massage, compression stockings, sequential pneumatic pumping, careful skincare, and surgery to remove swollen tissue or create new drainage routes.

The high prevalence of cancers, increasing innovations and technologies and rising number of players in the market, and novel product launches also propel the market's growth.

North America Lymphedema Treatment Market Dynamics

Drivers

  • Rise in the number of Lymphedema Cases

The collection of lymph fluid in fatty tissues close beneath the skin is called lymphedema. The ailment is caused by a person's poor lymphatic system flow, and it manifests itself in the legs, arms, or both. Primary lymphedema affects one to two million persons in the United States, while secondary lymphedema affects two to three million.

  • Increase in the Prevalence of Cancers

According to the National Cancer Institute, 1,806,590 new cancer cases will be identified in the United States in 2020, with 606,520 people dying from the disease.

According to the American Cancer Society, Inc, cancer is the main cause of death in Canada and the second-highest cause in the United States, behind heart disease. In 2018, it was anticipated that 1.9 million new cancer cases and 693,000 cancer deaths would occur in North America.

Furthermore, an increasing number of healthcare facilities and multiple therapies are the factors that will expand the lymphedema treatment market.  Additionally, the healthcare system requires highly advanced treatment products. Therefore, major players are highly focused on new and innovative product launches and approvals to drive the North America lymphedema treatment market. 

Get Exclusive Sample Copy of this Report Here

Opportunities

  • Drug Approvals

The market has witnessed numerous drug approvals in past years, driven by the increasing fatality rate of disease. Increasing drug approvals will ramp up the demand for the lymphedema treatment market.

In July 2015, Siltuximab was the first drug to be approved to treat multicentric castleman's disease under the FDA priority review program in the US. The multicentric castleman's disease enlarges the lymph nodes with characteristic findings in multiple lymph node regions.

Moreover, partnerships and agreements by major players in North America will boost new opportunities for the market's growth rate.

Restraints/Challenges

However, the high cost of treatment and lack of awareness about lymphedema restrains the market. Furthermore, no permanent cure for lymphedema and difficult reimbursement act as the challenge for the North America lymphedema treatment market

North America lymphedema treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.

COVID-19 Impact on North America Lymphedema Treatment Market

COVID-19 has positively affected the market. On March 11, 2020, COVID-19 was formally declared a pandemic. The COVID-19 pandemic has resulted in an unprecedented demand for healthcare resources since then.

The treatment of both primary and secondary lymphedema patients has been interrupted or delayed during COVID 19. There was a huge decrease in the number of patients visiting hospitals, which impacted the overall growth of the North America lymphedema treatment market. The COVID-19 impact has negatively affected the price of lymphedema treatment products because of the increased cost of drugs and medication prescribed for lymphedema and fewer doctor visits during the lockdown period.

According to United Nations Office on Drugs and Crime (UNODC), mobility restrictions, closed borders, and a decline in overall world trade during COVID-19 disrupted the supply chains of drug markets.

Moreover, many drugs are being produced at different locations, and due to the restrictions on movement, there has been a shortage in the drug supply. Therefore, COVID-19 has a negative impact on the supply chain of the North America lymphedema treatment market.

Recent Developments

  • In February 2020, Avet Pharmaceuticals Inc. announced that they acquired a portfolio of 23 abbreviated new drug applications (ANDAs), covering 17 product families, all previously approved by the U.S. Food and Drug Administration (FDA). This broadened the product portfolio of the company
  • In September 2021, Tactile Medical announced the enrollment of the first patient in a randomized, controlled clinical trial evaluating the effectiveness of Flexitouch plus for the treatment of head and neck lymphedema. This will increase the credibility of the company in the market

North America Lymphedema Treatment Market Scope

North America lymphedema treatment market is segmented based on treatment type, type, affected area, age group, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

  • Compression Therapy
  • Surgery
  • Drug Therapy
  • Laser Therapy
  • Others

On the basis of treatment type, the North America lymphedema treatment market is segmented into compression therapy, surgery, drug therapy, laser therapy, and others.

Type

  • Secondary Lymphedema
  • Primary Lymphedema

On the basis of type, the North America lymphedema treatment market is segmented into secondary lymphedema and primary lymphedema.

Affected Area

  • Lower Extremity
  • Upper Extremity
  • Genitalia

On the basis of affected area, the North America lymphedema treatment market is segmented into lower extremity, upper extremity, and genitalia

Age Group

  • Adult
  • Geriatric
  • Pediatric

On the basis of age group, the North America lymphedema treatment market is segmented into adult, geriatric, and pediatric.

Route of Administration

  • Oral
  • Injectable
  • Topical

On the basis of route of administration, the North America lymphedema treatment market is segmented into oral, injectable, and topical.

End User

  • Hospital
  • Speciality Clinics
  • Ambulatory Surgical Centers
  • Others

Based on end user, the North America lymphedema treatment market is segmented into hospital, speciality clinics, ambulatory surgical centers, and others.

Distribution Channel

  • Pharmacy Stores
  • Direct Tender
  • Others

Get Exclusive Sample Copy of this Report Here

Based on distribution channel, the North America lymphedema treatment market is segmented into pharmacy stores, direct tender, and others.

North America Lymphedema Treatment Market Regional Analysis/Insights

North America lymphedema treatment market is analyzed, and market size insights and trends are provided by country, treatment type, type, affected area, age group, route of administration, end user, and distribution channel as referenced above.

The countries covered in the North America lymphedema treatment market report are the U.S., Canada, and Mexico.

U.S. is expected to dominate the North America lymphedema treatment market due to the strong presence of market players and the rising prevalence of lymphedema diseases.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels is considered while providing forecast analysis of the country data.

Competitive Landscape and North America Lymphedema Treatment Market Share Analysis

North America lymphedema treatment market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North American presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points are only related to the companies' focus on the North America lymphedema treatment market.

Some of the major players operating in the North America lymphedema treatment market are Tactile Medical, BIOCOMPRESSION SYSTEMS, Lohmann & Rauscher GmbH & Co. KG, ThermoTek, Essity (BSN medical GmbH), Cardinal Health, Smith+Nephew, Avet Pharmaceuticals Inc., KOYA MEDICAL, SIGVARIS GROUP, AIROS Medical, Inc., Tactile Medical, medi GmbH & Co. KG, PAUL HARTMANN AG, Convatec Inc., 3M, JUZO, Mego Afek ltd, Huntleigh Healthcare Limited, HERANTIS PHARMA Plc, among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or can drop down your inquiry. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Africa versus Regional, and Vendor Share Analysis. To know more about the research methodology, drop an inquiry to speak to our industry experts.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA LYMPHEDEMA TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL'S ANALYSIS

4.2 PORTER'S MODEL

5 PIPELINE ANALYSIS FOR NORTH AMERICA LYMPHEDEMA TREATMENT MARKET

6 EPIDEMIOLOGY

7 REGULATORY GUIDELINES FOR NORTH AMERICA LYMPHEDEMA TREATMENT MARKET

7.1 U.S.

7.2 CANADA

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES

8.1.2 INCREASE IN THE PREVALENCE OF CANCERS

8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES

8.1.4 MULTIPLE THERAPIES

8.2 RESTRAINTS

8.2.1 HIGH COST OF TREATMENT

8.2.2 LACK OF AWARENESS ABOUT THE DISEASE

8.3 OPPORTUNITIES

8.3.1 DRUG APPROVALS

8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS

8.4 CHALLENGES

8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA

8.4.2 DIFFICULT REIMBURSEMENT

9 IMPACT OF COVID-19 ON THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET

9.1 IMPACT ON PRICE

9.2 IMPACT ON DEMAND

9.3 IMPACT ON SUPPLY CHAIN

9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS

9.5 CONCLUSION

10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE

10.1 OVERVIEW

10.2 COMPRESSION THERAPY

10.2.1 BY PRODUCT

10.2.1.1 COMPRESSION PUMPS

10.2.1.2 COMPRESSION GARMENTS

10.2.1.2.1 COMPRESSION STOCKINGS

10.2.1.2.2 COMPRESSION SLEEVES

10.2.1.2.3 OTHERS

10.2.1.3 COMPRESSION BANDAGES & WRAPS

10.2.1.4 OTHERS

10.2.2 BY TECHNIQUE

10.2.2.1 STATIC COMPRESSION THERAPY

10.2.2.2 DYNAMIC COMPRESSION THERAPY

10.3 SURGERY

10.3.1 LYMPHOVENOUS TRANSPLANT

10.3.2 LYMPHATICOVENOUS ANASTOMOSIS

10.3.3 LIPOSUCTION

10.3.4 OTHERS

10.4 DRUG THERAPY

10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)

10.4.2 RETINOIDS

10.4.3 ANTIBIOTICS

10.4.4 OTHERS

10.5 LASER THERAPY

10.6 OTHERS

11 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE

11.1 OVERVIEW

11.2 SECONDARY LYMPHEDEMA

11.3 PRIMARY LYMPHEDEMA

11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE)

11.3.2 CONGENITAL LYMPHEDEMA

11.3.3 LYMPHEDEMA TARDA

12 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA

12.1 OVERVIEW

12.2 LOWER EXTREMITY

12.3 UPPER EXTREMITY

12.4 GENITALIA

13 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP

13.1 OVERVIEW

13.2 ADULT

13.3 GERIATRIC

13.4 PEDIATRIC

14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

14.1 OVERVIEW

14.2 ORAL

14.3 INJECTABLE

14.4 TOPICAL

15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITAL

15.3 SPECIALTY CLINICS

15.4 AMBULATORY SURGICAL CENTERS

15.5 OTHERS

16 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 PHARMACY STORES

16.3 DIRECT TENDER

16.4 OTHERS

17 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY REGION

17.1 OVERVIEW

17.2 U.S.

17.3 CANADA

17.4 MEXICO

18 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

19 SWOT ANALYIS

20 COMPANY PROFILE

20.1 TACTILE MEDICAL

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 PRODUCT PORTFOLIO

20.1.4 RECENT DEVELOPMENT

20.1.5 CLINICAL TRIAL:

20.2 ESSITY (BSN MEDICAL GMBH)

20.2.1 COMPANY SNAPSHOT

20.2.2 PRODUCT PORTFOLIO

20.2.3 RECENT DEVELOPMENT

20.3 3M

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 PRODUCT PORTFOLIO

20.3.4 RECENT DEVELOPMENTS

20.3.5 NEW BUSINESS SEGMENT

20.3.6 ACQUISITION

20.4 CARDINAL HEALTH

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 PRODUCT PORTFOLIO

20.4.4 RECENT DEVELOPMENT

20.5 LOHMANN & RAUSCHER GMBH & CO. KG

20.5.1 COMPANY SNAPSHOT

20.5.2 PRODUCT PORTFOLIO

20.5.3 RECENT DEVELOPMENT

20.6 AIROS MEDICAL, INC.

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENT

20.6.4 PRODUCT LAUNCH:

20.7 AVET PHARMACEUTICALS INC.

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENT

20.8 BIOCOMPRESSION SYSTEMS

20.8.1 COMPANY SNAPSHOT

20.8.2 PRODUCT PORTFOLIO

20.8.3 RECENT DEVELOPMENT

20.8.4 AGREEMENT

20.9 CONVATEC INC.

20.9.1 COMPANY SNAPSHOT

20.9.2 PRODUCT PORTFOLIO

20.9.3 RECENT DEVELOPMENT

20.1 HERANTIS PHARMA PLC

20.10.1 COMPANY SNAPSHOT

20.10.2 RECENT DEVELOPMENT

20.11 HUNTLEIGH HEALTHCARE LIMITED

20.11.1 COMPANY SNAPSHOT

20.11.2 PRODUCT PORTFOLIO

20.11.3 RECENT DEVELOPMENT

20.12 JUZO

20.12.1 COMPANY SNAPSHOT

20.12.2 PRODUCT PORTFOLIO

20.12.3 RECENT DEVELOPMENT

20.13 KOYA MEDICAL

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENT

20.13.4 APPROVAL

20.14 MEDI GMBH & CO. KG

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENT

20.15 MEGO AFEK LTD

20.15.1 COMPANY SNAPSHOT

20.15.2 PRODUCT PORTFOLIO

20.15.3 RECENT DEVELOPMENT

20.15.4 APPLICATION LAUNCH:

20.16 PAUL HARTMANN AG

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENTS

20.17 SIGVARIS GROUP

20.17.1 COMPANY SNAPSHOT

20.17.2 PRODUCT PORTFOLIO

20.17.3 RECENT DEVELOPMENTS

20.17.4 PRODUCT LAUNCHES:

20.18 SMITH +NEPHEW

20.18.1 COMPANY SNAPSHOT

20.18.2 REVENUE ANALYSIS

20.18.3 PRODUCT PORTFOLIO

20.18.4 RECENT DEVELOPMENT

20.19 THERMOTEK

20.19.1 COMPANY SNAPSHOT

20.19.2 PRODUCT PORTFOLIO

20.19.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

List of Table

TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT:

TABLE 2 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 16 U.S. LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 17 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 18 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 19 U.S. COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 20 U.S. SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 21 U.S. DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 22 U.S. LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 23 U.S. PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 24 U.S. LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 25 U.S. LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 26 U.S. LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 27 U.S. LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 U.S. LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 29 CANADA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 30 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 31 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 32 CANADA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 33 CANADA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 34 CANADA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 35 CANADA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 CANADA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 CANADA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 38 CANADA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 39 CANADA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 40 CANADA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 CANADA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 43 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 44 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 45 MEXICO COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 46 MEXICO SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 47 MEXICO DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 48 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 MEXICO PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 51 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 52 MEXICO LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 53 MEXICO LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 54 MEXICO LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : SEGMENTATION

FIGURE 2 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DROC ANALYSIS

FIGURE 4 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: REGIONAL VS COUNTRY ANALYSIS

FIGURE 5 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : MARKET APPLICATION COVERAGE GRID

FIGURE 9 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LYMPHEDEMA TREATMENT MARKET

FIGURE 14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2021

FIGURE 15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2020-2029 (USD MILLION)

FIGURE 16 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2022-2029)

FIGURE 17 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 18 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2021

FIGURE 19 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2020-2029 (USD MILLION)

FIGURE 20 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 21 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2021

FIGURE 23 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2020-2029 (USD MILLION)

FIGURE 24 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2022-2029)

FIGURE 25 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE

FIGURE 26 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2021

FIGURE 27 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2020-2029 (USD MILLION)

FIGURE 28 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2022-2029)

FIGURE 29 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 30 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 31 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

FIGURE 32 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 33 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 34 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2021

FIGURE 35 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 36 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 37 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 39 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

FIGURE 40 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL ,CAGR (2022-2029)

FIGURE 41 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 43 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 44 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 45 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 46 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE (2022-2029)

FIGURE 47 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2021 (%)

View Infographics

FIGURE 1 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : SEGMENTATION

FIGURE 2 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DROC ANALYSIS

FIGURE 4 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: REGIONAL VS COUNTRY ANALYSIS

FIGURE 5 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : MARKET APPLICATION COVERAGE GRID

FIGURE 9 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LYMPHEDEMA TREATMENT MARKET

FIGURE 14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2021

FIGURE 15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2020-2029 (USD MILLION)

FIGURE 16 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2022-2029)

FIGURE 17 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 18 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2021

FIGURE 19 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2020-2029 (USD MILLION)

FIGURE 20 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 21 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2021

FIGURE 23 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2020-2029 (USD MILLION)

FIGURE 24 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2022-2029)

FIGURE 25 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE

FIGURE 26 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2021

FIGURE 27 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2020-2029 (USD MILLION)

FIGURE 28 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2022-2029)

FIGURE 29 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 30 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 31 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

FIGURE 32 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 33 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 34 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2021

FIGURE 35 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 36 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 37 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 39 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

FIGURE 40 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL ,CAGR (2022-2029)

FIGURE 41 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 43 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 44 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 45 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 46 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE (2022-2029)

FIGURE 47 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2021 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19